Summary

Eligibility
for males ages 18 years and up (full criteria)
Location
at San Francisco, California and other locations
Dates
study started
study ends around

Description

Summary

The primary objectives of this study are to evaluate the safety and tolerability of xaluritamig administered in the neoadjuvant setting followed by radical prostatectomy and to evaluate the feasibility and safety of a radical prostatectomy following xaluritamig administered in the neoadjuvant setting.

Official Title

A Phase 1b, Open-Label, Multicenter Study Evaluating the Safety, Tolerability, and Feasibility of Neoadjuvant Xaluritamig Therapy Prior to Radical Prostatectomy in Subjects With Newly Diagnosed Localized Intermediate or High-Risk Prostate Cancer

Keywords

Prostate Cancer, Xaluritamig, AMG509, Localized Prostate Cancer, Neoadjuvant Therapy, Immunotherapy, T-Cell Engager, STEAP1, Prostatic Neoplasms

Eligibility

You can join if…

Open to males ages 18 years and up

Participants are eligible to be included in the study only if all the following criteria apply:

  • Participants planned to undergo radical prostatectomy.
  • Histologically or cytologically confirmed adenocarcinoma of the prostate at initial biopsy, without neuroendocrine differentiation, signet cell, or small cell features.

    Intermediate- or high-risk localized prostate cancer, defined as:

  • Gleason score of 4+3 or higher AND initial PSA (iPSA) >10 OR
  • Clinically advanced (cT3) on Magnetic Resonance Imaging (MRI) obtained within 3 months prior to screening AND/OR
  • Positive locoregional lymph nodes as detected by prostate-specific membrane antigen-positron emission tomography (PSMA-PET) scans OR equal or ≤ 5 local lymph nodes on MRI can be enrolled.
  • Participants must have undergone a PSMA-PET (CT or MRI) scan within 3 months prior to screening as part of the standard of care (SOC).
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.

You CAN'T join if...

Participants are excluded from the study if any of the following criteria apply:

  • Prior treatment for participant's prostate cancer.
  • Any evidence of metastases outside of the surgical resection field identified by conventional imaging or PSMA-PET scans.
  • Confirmed history or current autoimmune disease or other diseases resulting in permanent immunosuppression or requiring permanent immunosuppressive therapy.
  • Participants with symptoms and/or clinical signs and/or radiographic signs that indicate an acute and/or uncontrolled active systemic infection within 7 days prior to the first dose of study treatment:
  • Participant has known active infection requiring antibiotic treatment. Upon completion of antibiotics and resolution of symptoms, the participant may be considered eligible for the study from an infection standpoint.
  • Recent history of arterial or venous thrombosis (eg, stroke, transient ischemic attack, pulmonary embolism, or deep vein thrombosis) within 6 and 3 months prior to the first dose of study treatment, respectively. Note: Participants with a history of venous thrombosis must be on stable anti-coagulation.
  • Myocardial infarction and/or symptomatic congestive heart failure (New York Heart Association ≥ class II) within 12 months of first dose of xaluritamig with the exception of ischemia or non-ST segment elevation myocardial infarction controlled with stent placement more than 6 months prior to first dose of xaluritamig.
  • Requirement for chronic systemic corticosteroid therapy unless stopped (with adequate tapering) within 7 days prior to dosing.
  • Currently receiving treatment in another investigational device or drug study, or less than 4 weeks (since ending treatment on another investigational device or drug study[ies]). Other investigational procedures and participation in observational research studies while participating in this study are excluded with the exception of investigational scans.

Locations

  • UCSF accepting new patients
    San Francisco California 94143 United States
  • Washington University accepting new patients
    Saint Louis Missouri 63110 United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Amgen
Links
AmgenTrials clinical trials website
ID
NCT06613100
Phase
Phase 1 Prostate Cancer Research Study
Study Type
Interventional
Participants
Expecting 40 study participants
Last Updated